4890 Stock Overview
Engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Tsubota Laboratory Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥361.00 |
| 52 Week High | JP¥738.00 |
| 52 Week Low | JP¥252.00 |
| Beta | 0 |
| 1 Month Change | -4.75% |
| 3 Month Change | -2.70% |
| 1 Year Change | -49.65% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -57.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4890 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 1.4% | -3.7% | -1.9% |
| 1Y | -49.7% | -2.3% | 16.4% |
Return vs Industry: 4890 underperformed the JP Pharmaceuticals industry which returned -2.3% over the past year.
Return vs Market: 4890 underperformed the JP Market which returned 16.4% over the past year.
Price Volatility
| 4890 volatility | |
|---|---|
| 4890 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4890's share price has been volatile over the past 3 months.
Volatility Over Time: 4890's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 10 | Kazuo Tsubota | www.tsubota-lab.com |
Tsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan.
Tsubota Laboratory Incorporated Fundamentals Summary
| 4890 fundamental statistics | |
|---|---|
| Market cap | JP¥9.23b |
| Earnings (TTM) | -JP¥641.00m |
| Revenue (TTM) | JP¥673.00m |
13.7x
P/S Ratio-14.4x
P/E RatioIs 4890 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4890 income statement (TTM) | |
|---|---|
| Revenue | JP¥673.00m |
| Cost of Revenue | JP¥653.00m |
| Gross Profit | JP¥20.00m |
| Other Expenses | JP¥661.00m |
| Earnings | -JP¥641.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
| Earnings per share (EPS) | -25.06 |
| Gross Margin | 2.97% |
| Net Profit Margin | -95.25% |
| Debt/Equity Ratio | 8.5% |
How did 4890 perform over the long term?
See historical performance and comparison